NEWS RELEASE

Submitted by amarin on Fri, 08/05/2022 - 09:49
Duis autem vel eum iriure dolor in ss hendrerit in vulputate velit esse fdas molestie consequatgdsfdasfdsaffse Duis autem vel eum iriure dolor in ss hendrerit in vulputate velit esse fdas

Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update

Submitted by amarin on Wed, 08/03/2022 - 11:01
Company Received Final Positive Reimbursement Decision for VAZKEPA ® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S.